13-Butyl-6-methylene-4,8-di(p-toluenesulfonyl)-4,8,15-triazabicyclo[9.3.1]pentadeca-1(15),11,13-triene Hydrochloride

ID: ALA4750983

Chembl Id: CHEMBL4750983

PubChem CID: 162650959

Max Phase: Preclinical

Molecular Formula: C31H40ClN3O4S2

Molecular Weight: 581.80

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  C=C1CN(S(=O)(=O)c2ccc(C)cc2)CCc2cc(CCCC)cc(n2)CCN(S(=O)(=O)c2ccc(C)cc2)C1.Cl

Standard InChI:  InChI=1S/C31H39N3O4S2.ClH/c1-5-6-7-27-20-28-16-18-33(39(35,36)30-12-8-24(2)9-13-30)22-26(4)23-34(19-17-29(21-27)32-28)40(37,38)31-14-10-25(3)11-15-31;/h8-15,20-21H,4-7,16-19,22-23H2,1-3H3;1H

Standard InChI Key:  ZGIALFWYYRKJAO-UHFFFAOYSA-N

Associated Targets(Human)

CD4 Tclin T-cell surface antigen CD4 (114 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MT4 (17854 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Human immunodeficiency virus 1 (70413 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 581.80Molecular Weight (Monoisotopic): 581.2382AlogP: 5.08#Rotatable Bonds: 7
Polar Surface Area: 87.65Molecular Species: NEUTRALHBA: 5HBD:
#RO5 Violations: 2HBA (Lipinski): 7HBD (Lipinski): #RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: 4.59CX LogP: 6.03CX LogD: 6.03
Aromatic Rings: 3Heavy Atoms: 40QED Weighted: 0.36Np Likeness Score: -0.44

References

1. Lumangtad LA,Claeys E,Hamal S,Intasiri A,Basrai C,Yen-Pon E,Beenfeldt D,Vermeire K,Bell TW.  (2020)  Syntheses and anti-HIV and human cluster of differentiation 4 (CD4) down-modulating potencies of pyridine-fused cyclotriazadisulfonamide (CADA) compounds.,  28  (24): [PMID:33181479] [10.1016/j.bmc.2020.115816]

Source